Peripheral transcriptome of clinical high‐risk psychosis reflects symptom alteration and helps prognosis prediction.
Saved in:
| Title: | Peripheral transcriptome of clinical high‐risk psychosis reflects symptom alteration and helps prognosis prediction. |
|---|---|
| Authors: | Song, Weichen (AUTHOR), Xu, Lihua (AUTHOR), Zhang, Tianhong (AUTHOR), Wang, Weidi (AUTHOR), Fu, Yingmei (AUTHOR), Xu, Qingqing (AUTHOR), Yuan, Ruixue (AUTHOR), Ning, Ailing (AUTHOR), Wang, Jijun (AUTHOR), Lin, Guan Ning (AUTHOR), Yu, Shunying (AUTHOR) |
| Source: | Psychiatry & Clinical Neurosciences. Jun2022, Vol. 76 Issue 6, p268-270. 3p. 1 Graph. |
| Subjects: | Transcriptomes, Prognosis, Symptoms, Cell adhesion molecules, Psychoses |
| Abstract: | Clinical high-risk psychosis (CHR-P)1 refers to a heterogeneous state where patients exhibit psychotic syndromes such as hallucination and delusion not reaching the diagnostic criteria, with the ability of self-reasoning and help-seeking partially maintained. Thus, blood transcriptome is valuable to CHR-P's clinical intervention, where treatment choices are dependent on the objective evaluation of symptom severity and conversion risk.9 In addition, our symptom association model also reflected the underlying biological mechanism, such as downregulation of synaptic vesicle recycling during CHR-P progression. Methods To evaluate whether blood RNA could serve as CHR-P biomarkers, we collected blood samples of patients with CHR-P from the Shanghai at-risk psychosis (SHARP) longitudinal cohort7 and applied RNA sequencing. Peripheral transcriptome of clinical high-risk psychosis reflects symptom alteration and helps prognosis prediction. [Extracted from the article] |
| Copyright of Psychiatry & Clinical Neurosciences is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Clinical high-risk psychosis (CHR-P)1 refers to a heterogeneous state where patients exhibit psychotic syndromes such as hallucination and delusion not reaching the diagnostic criteria, with the ability of self-reasoning and help-seeking partially maintained. Thus, blood transcriptome is valuable to CHR-P's clinical intervention, where treatment choices are dependent on the objective evaluation of symptom severity and conversion risk.9 In addition, our symptom association model also reflected the underlying biological mechanism, such as downregulation of synaptic vesicle recycling during CHR-P progression. Methods To evaluate whether blood RNA could serve as CHR-P biomarkers, we collected blood samples of patients with CHR-P from the Shanghai at-risk psychosis (SHARP) longitudinal cohort7 and applied RNA sequencing. Peripheral transcriptome of clinical high-risk psychosis reflects symptom alteration and helps prognosis prediction. [Extracted from the article] |
|---|---|
| ISSN: | 13231316 |
| DOI: | 10.1111/pcn.13346 |
